先健科技涨超7% IBS Angel™铁基可吸收支架系统获马来西亚注册批准
格隆汇6月10日丨先健科技(1302.HK)一度涨超7%报5.3港元,股价创今年1月以来新高,市值245亿港元。先健科技(1302.HK)是医疗器械行业高值耗材领域的龙头企业之一,公司今日宣布,其控股子公司元心科技自主研发的创新产品IBS Angel™铁基可吸收支架系统(“IBS Angel™”)于6月8日获马来西亚药监局MDA颁发的注册证,成为全球首个商业化的铁基可吸收血管支架,填补了儿童肺血管狭窄治疗的国际空白。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.